Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Childhood Adenotonsillectomy Study for Children With OSAS (CHAT)
This study is currently recruiting participants.
Verified by University of Pennsylvania, November 2007
Sponsors and Collaborators: University of Pennsylvania
Case Western Reserve University
University of Michigan
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00560859
  Purpose

The purpose of this research is to determine the effect of adenotonsillectomy surgery (removal of tonsils and adenoids) on obstructive sleep apnea syndrome (OSAS) in children. OSAS can cause health problems including poor growth, high blood pressure, diabetes and behavioral and learning difficulties. Although adenotonsillectomy is the usual treatment for children with OSAS, it is not known with any certainty if the child's OSAS symptoms improve afterwards. This study will help determine if improvement occurs or if it does not. It will also look at whether certain groups, such as children who are overweight or of different ethnicities, are helped by the surgery.


Condition Intervention
Obstructive Sleep Apnea
Snoring
Procedure: Adenotonsillectomy (AT) - removal of adenoids and tonsils
Other: Watchful Waiting

MedlinePlus related topics: Sleep Apnea Snoring Tonsils and Adenoids
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Investigator), Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • To determine improvements in neurocognitive functioning post surgery, the Attention/Executive Domain Index of the Developmental Neuropsychological Assessment (NEPSY), will be compared between the two arms. [ Time Frame: The primary endpoint measure will occur at 7 months following the baseline visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The Apnea Hypopnea Index (AHI) score will be compared between the two groups to determine whether an improvement in score is associated with improved OSAS (i.e. reduction in AHI). [ Time Frame: 7 months following the baseline visit. ] [ Designated as safety issue: No ]
  • To determine the effects of AT surgery on subgroups by race and weight. [ Time Frame: 7 months following baseline. ] [ Designated as safety issue: No ]

Estimated Enrollment: 460
Study Start Date: October 2007
Estimated Study Completion Date: January 2010
Arms Assigned Interventions
Early AT Surgery: Active Comparator
Children will be closely monitored and receive adenotonsillectomy (AT) within 4 weeks of the baseline visit.
Procedure: Adenotonsillectomy (AT) - removal of adenoids and tonsils
Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome.
Watchful Waiting
Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
Other: Watchful Waiting
Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.

Detailed Description:

Because adenotonsillectomy is the usual treatment for OSAS, all children in the study will get surgery. However, in order to assess the extent to which adenotonsillectomy surgery improves breathing disturbances and sleep quality in children with OSAS, two groups will be studied. One group will get surgery early (one month after enrollment) and the other group will be re-evaluated for surgery within 7 months of enrollment.

Children in both groups will be closely monitored throughout the 12 month study period and sleep and health educational materials will be provided to assist in establishing healthy habits.

  Eligibility

Ages Eligible for Study:   5 Years to 9 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ages 5.0 to 9.99 years at time of screening.
  2. Diagnosed with Obstructive Sleep Apnea defined as: Obstructive Apnea Index (OAI) ≥ 1 or Apnea Hypopnea Index (AHI) ≥ 2, confirmed on nocturnal, laboratory-based PSG and Parental report of habitual snoring (on average occurring >3 nights per week).
  3. Tonsillar hypertrophy ≥ 2 based on a standardized scale of 0-4: 0 = surgically absent, 1 = taking up < 25% of the airway,2 = 25 - 50 % of the airway,3 = 50 - 75 % of the airway, 4 = > 75% of the airway
  4. Deemed to be a surgical candidate for AT by ENT evaluation.

Exclusion Criteria:

  1. Recurrent tonsillitis defined as: > 3 episodes in each of 3 years, 5 episodes in each of 2 years, or 7 episodes in one year.
  2. Craniofacial anomalies, including cleft lip and palate or sub-mucosal cleft palate or any anatomic or systemic condition which would interfere with general anesthesia or removal of tonsils and adenoid tissue in the standard fashion.
  3. Obstructive breathing while awake that merits prompt AT in the opinion of the child's physician.
  4. Severe OSAS or significant hypoxemia requiring immediate AT as defined by:

    OAI > 20 or AHI > 30, Desaturation defined as SaO2 <90% for more than 2% sleep time

  5. Apnea hypopnea indices in the normal range (OAI < 1 and AHI <2)
  6. Evidence of clinically significant cardiac arrhythmia on PSG: Non-sustained ventricular tachycardia Atrial fibrillation, Second degree AV block: Sustained bradycardia < 40 bpm (> 2 minutes,Sustained tachycardia > 140 bpm (> 2 minutes)
  7. Extremely overweight defined as: body mass index > 2.5 age group and sex-z-score
  8. Severe health problems that could be exacerbated by delayed treatment for OSAS Including: Doctor-diagnosed heart disease or cor pulmonale, history of Stage II Hypertension (HTN) defined as > 99% percentile plus 5 mmHg for either systolic or diastolic, based on the age, gender, and height and/or requiring medication, therapy for failure to thrive or short stature, psychiatric or behavioral disorders requiring or likely to require initiation of new medication, therapy, or other specific treatment. School aged children, parental report of excessive daytime sleepiness defined as unable to maintain wakefulness, at least three times per week, in routine activities in school or home, despite adequate opportunity to sleep.
  9. Severe chronic health conditions that might hamper participation including: severe cardiopulmonary disorders, sickle cell anemia, poorly controlled asthma, epilepsy requiring medication, diabetes (type I or type II) requiring medication, conditions likely to preclude accurate polysomnography (e.g. severe uncontrolled pain),mental retardation or enrollment in a formal school Individual Educational Plan (IEP) and assigned to a self-contained classroom for all academic subjects, history of inability to complete cognitive testing and/or score on DAS II of ≤ 55, chronic infection or HIV
  10. Known genetic, craniofacial, neurological or psychiatric conditions likely to affect the airway, cognition, or behavior
  11. Current use of one or more of the following medications: ADHD,psychotropics, hypnotics,hypoglycemic agents or insulin,antihypertensives,growth hormone, anticonvulsants,anti-coagulants,daily oral corticosteroids, daily medications for pain
  12. Previous upper airway surgery on the nose, pharynx or larynx, including adenoidectomy. Ear surgery and/or PE tubes are not exclusion criteria.
  13. Receives Continuous Positive Airway Pressure (CPAP) treatment
  14. A parent or guardian who cannot accompany the child on the night of PSG
  15. A parent or guardian who cannot read and understand the consent form; including families unable to understand or complete the standardized English language assessment forms and testing instruments
  16. A family planning to move out of the area within the year
  17. Female participants only: Parental report that child has reached menarche.

    -

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00560859

Locations
United States, Kentucky
Kosair Children's Hospital Recruiting
Louisville, Kentucky, United States, 40202
Contact: Dianna O'Neal, RN     502-852-5303     dconea01@gwise.louisville.edu    
Principal Investigator: David Gozal, MD            
Sub-Investigator: Karen Spruyt, Ph.D.            
Sub-Investigator: Maria Veling, MD            
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Jenny Jeffries     513-636-1052     jenny.jeffries@cchmc.org    
Contact: Ashley Morgenthal     513-636-9436     ashley.morgenthal@cchmc.org    
Principal Investigator: Raouf Amin, MD            
Sub-Investigator: Dean W Beebe, Ph.D.            
Sub-Investigator: J. Paul Willging, MD            
Rainbow Babies & Children's Hospital Recruiting
Cleveland, Ohio, United States, 44106
Contact: Judith Emancipator     216-844-2553     judith.emancipator@case.edu    
Principal Investigator: Carol Rosen, MD            
Sub-Investigator: H. Gerry Taylor, Ph.D.            
Sub-Investigator: Robert Sprecher, MD            
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19401
Contact: Laurie Karremensis     267-426-5748     karamessinis@email.chop.edu    
Contact: Ruth M Bradford     267-426-5747     bradford@email.chop.edu    
Principal Investigator: Carole Marcus, MBB Ch            
Sub-Investigator: Nina Hattiangadi-Thomas, Ph.D.            
Sub-Investigator: Lisa Elden, MD            
Sponsors and Collaborators
University of Pennsylvania
Case Western Reserve University
University of Michigan
Investigators
Study Chair: Susan Redline, MD, MPH Case Western Reserve University
Study Director: Susan Ellenberg, Ph.D. University of Pennsylvania
Principal Investigator: Ron Chervin, MD, MS University of Michigan
Study Director: Bruno Giordani, PH.D. Univeristy of Michigan
Study Director: Susan Garetz, MD University of Michigan
Principal Investigator: Raouf Amin, MD Cincinnati Children's Hopsital Medical Center (CCHMC)
Principal Investigator: David Gozal, MD University of Louisville; Kosair Children's Hospital
Principal Investigator: Carole Marcus, MBB Ch. Children's Hospital of Philadelphia (CHOP)
Principal Investigator: Carol Rosen, MD Case University School of Medicine; Rainbow Babies & Children's Hospital
  More Information

Parent/Child Sleep Education  This link exits the ClinicalTrials.gov site
National Center on Sleep Disorder Research  This link exits the ClinicalTrials.gov site

Responsible Party: Case Western Reserve University ( Susan Redline, MD, MPH )
Study ID Numbers: 804695, 1 R01 HL083129-01A1
Study First Received: November 19, 2007
Last Updated: November 29, 2007
ClinicalTrials.gov Identifier: NCT00560859  
Health Authority: United States: Federal Government;   United States: Institutional Review Board

Keywords provided by University of Pennsylvania:
Sleep disordered breathing
Sleep apnea
Tonsillectomy
Adenoidectomy
Snoring
Neurobehavioral Manifestations
Obstructive Sleep Apnea Syndrome

Study placed in the following topic categories:
Sleep Apnea Syndromes
Respiratory Sounds
Apnea
Sleep Apnea, Obstructive
Respiration Disorders
Snoring
Sleep Disorders
Dyssomnias
Sleep Disorders, Intrinsic
Signs and Symptoms
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Neurobehavioral Manifestations

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 15, 2009